Melanoma

This phase II trial is testing whether a combination of two drugs, rigosertib and pembrolizumab, can help people with advanced melanoma that no longer responds to standard immunotherapy. The study involves 7 participants with unresectable or metastatic melanoma. The goal is to se…

Researchers are testing an experimental immunotherapy called ALT-801 alongside the chemotherapy drug cisplatin in people with metastatic melanoma that cannot be cured with surgery. The trial enrolls about 22 participants who have not received prior chemotherapy for their melanoma…

This study tested whether adding vibostolimab to the standard immunotherapy pembrolizumab can better prevent melanoma from returning after surgery. About 1,600 people with high-risk stage II to IV melanoma took part. The goal was to see if the combination keeps cancer away longer…

This early-stage trial tests a radioactive drug called [225Ac]Ac-A9-3408 in 50 adults with melanoma that has spread or can't be removed by surgery. The main goals are to find a safe dose and check for side effects. Participants receive the drug every 6 weeks for up to 6 doses, an…

This early-phase trial tested ASP1012, a virus engineered to infect and kill cancer cells while making them visible to the immune system. It was given alone or with the immunotherapy pembrolizumab to 15 adults with advanced solid tumors. The main goals were to check safety and fi…

This study tests a new treatment for people with advanced melanoma that has come back or not responded to standard therapy. The treatment uses specially engineered immune cells (CAR-T cells) that target two proteins, NG2 and DLL3, found on melanoma cells. The goal is to see if th…

This trial is testing whether combining two drugs—pembrolizumab and lenvatinib—can help people with metastatic uveal melanoma, a rare eye cancer that has spread to other parts of the body. Participants receive both drugs for up to two years. The study measures how long people liv…

This trial explores whether adding counseling, cognitive behavioural therapy, or hypnotherapy to nicotine replacement therapy can help cancer patients quit smoking before their surgery. The study includes adults with breast, digestive, gynecologic cancer, or melanoma who smoke da…

This study tested two drugs, encorafenib and binimetinib, given before surgery to people with stage IIIB-D melanoma that had spread to lymph nodes. The goal was to see if the drugs could shrink or eliminate the cancer before removal. The trial was stopped early after enrolling on…

This study tested whether adding hydroxychloroquine (a malaria drug) to standard targeted therapy (dabrafenib and trametinib) could help control advanced melanoma that had spread or could not be removed by surgery. It was designed for people with a specific gene mutation (BRAF V6…

This phase 2 trial tests whether combining high-dose IL-2 with nivolumab can shrink tumors in people with advanced melanoma or kidney cancer that has progressed despite prior anti-PD-1 therapy. Participants receive nivolumab and high-dose IL-2 in repeated cycles, and researchers …

This trial is testing an experimental drug called NUC-3373, a nucleotide analogue, in combination with standard cancer drugs for people with advanced solid tumors. The study has two parts: one combining NUC-3373 with pembrolizumab, and the other combining it with docetaxel. The g…

This early-stage trial tested an oral drug called TNO155, alone or with another drug (nazartinib), in 227 adults with advanced solid tumors like lung cancer, melanoma, and head/neck cancer. The main goal was to check safety and find the right dose. The study was terminated early,…

This study tested a new drug called acasunlimab, given alone or with pembrolizumab, in people with advanced melanoma that had stopped responding to standard treatments. The trial was terminated early after enrolling only one participant, so no conclusions can be drawn about safet…

This early-stage study tests a new drug, PF-08046049/SGN-BB228, in people with advanced melanoma and other solid tumors that have spread or stopped responding to standard treatments. The main goal is to check the drug's safety and find the best dose. About 41 participants will ta…

This study tested whether adding timolol gel to pulsed dye laser treatment could improve results for port wine stains on children's faces. Twenty-five children aged 6 months to 18 years were enrolled, but the study was stopped early. The goal was to see if the combination led to …

This early-stage study tested a new drug called CLN-617, alone or with the immunotherapy Keytruda, in 23 adults with advanced solid tumors that had not responded to standard treatments. The goal was to check safety and find the right dose. However, the trial was terminated, so fu…

This early-stage trial tested a two-step radioimmunotherapy combining GD2-SADA and 177Lu-DOTA in patients with recurrent or metastatic solid tumors, including small cell lung cancer, high-risk neuroblastoma, sarcoma, and melanoma. The goal was to assess safety and find the right …

This study tested a new combination treatment for people with advanced melanoma that cannot be removed by surgery or has spread. The combination included an experimental drug injected into tumors (CMP-001) plus an immunotherapy given through a vein (nivolumab). It was compared to…

This study tested two different proton therapy schedules for people with large choroidal melanomas (eye cancer) that would normally require removal of the eye. The goal was to see if a gentler radiation schedule could control the tumor and avoid severe side effects, allowing pati…

This early-stage study tested a new drug called PF-07265807 in people with advanced or metastatic solid tumors that had spread. The main goals were to find a safe dose and check for side effects. The trial was terminated early, so results are limited.

This study tested a combination of two drugs, pembrolizumab and lenvatinib, in 18 adults with melanoma or kidney cancer that had spread to the brain. Participants had already received anti-PD-1/PD-L1 therapy. The goal was to see if the drug combo could shrink or eliminate brain t…

This early-stage trial tested a combination of an experimental fusion protein (hu14.18-IL2), radiation, and two immunotherapy drugs (nivolumab and ipilimumab) in people with advanced melanoma that couldn't be surgically removed. The goal was to find the safest dose and check for …

This phase III trial compared two radiation strategies for cancer that had spread to the brain and returned in new spots after initial radiosurgery. One group received focused radiation only to the new tumors, while the other received whole brain radiation that avoided the memory…

This study tested a personalized treatment using immune cells taken from a patient's own tumor, called tumor-infiltrating lymphocytes (TIL). The cells were grown in a lab and given back to the patient to fight their cancer. The trial included people with advanced melanoma, head a…

This early-phase study tested a new drug called PF-08046032, given alone or with another drug (sasanlimab), in adults with advanced lymphomas or solid tumors like lung cancer and melanoma. The trial aimed to check safety and find the right dose, but it was terminated early after …

This early-phase trial tested the drug plinabulin combined with radiation and immunotherapy in 19 people with advanced cancers (like lung, bladder, or melanoma) that had stopped responding to standard immunotherapy. The goal was to see if the combination was safe and could shrink…

This phase II trial tested whether adding radiotherapy to the immunotherapy drug pembrolizumab could better control advanced melanoma than pembrolizumab alone. Only 17 people took part before the study was stopped early. The goal was to see if radiation could trigger an 'abscopal…

This study tested a combination of two drugs, ipilimumab and epacadostat, in people with advanced melanoma that could not be removed by surgery or had spread. The goal was to see if adding epacadostat to standard treatment improved survival. However, the study was stopped early f…

This early-stage study tested a new drug called PF-08046037, alone or with another drug (sasanlimab), in 8 people with advanced lung, pancreatic, melanoma, or head & neck cancers. The goal was to check safety and how the body handles the drugs. The trial was terminated early, so …

This early-stage trial tested an investigational drug called TransCon TLR7/8 agonist, alone or with the immunotherapy pembrolizumab, in people with advanced solid tumors that could not be cured by surgery or radiation. The study aimed to find a safe dose and check for side effect…

This early-stage study tested a new drug combination (MGN1703 plus ipilimumab) in people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to find the safest dose of MGN1703 when given with ipilimumab. The study was stopped early, bu…

This early-phase trial tested a new drug called nanrilkefusp alfa, which helps activate immune cells, both alone and combined with the immunotherapy pembrolizumab. It included 115 people with various advanced solid tumors that had stopped responding to standard treatments. The st…

This early-phase study tested a new drug called PF-07921585, given alone or with another drug (sasanlimab), in adults with advanced solid tumors like lung, bladder, kidney, melanoma, head & neck, or colorectal cancer. The goal was to check safety and find the right dose. Only 4 p…

This early-phase study tested a treatment using donated natural killer (NK) cells from cord blood, combined with chemotherapy, for children and young adults with solid tumors that returned or didn't respond to standard care. The goal was to find the safest dose and check for side…

This early-stage study tested a new drug called PF-08046031 in 11 adults with advanced melanoma or other solid tumors that had spread or had no standard treatment options. The main goal was to check the drug's safety and side effects. The trial was terminated early, so its findin…

This study tested a combination of two drugs, bintrafusp alfa and pimasertib, in people whose cancer had spread to the brain. The goal was to find the safest dose and see if the treatment could slow or stop the cancer from growing. The trial was stopped early after enrolling only…

This phase II trial tested the drug imatinib in 13 adults with metastatic ocular melanoma, a rare eye cancer that has spread. The goal was to see if imatinib could stop tumor growth for at least 3 months. The trial was terminated early, so the results are limited and it is unclea…

This study tested whether a three-drug combination (encorafenib, binimetinib, and pembrolizumab) works better than a two-drug combo (ipilimumab and nivolumab) for people with advanced melanoma that has a BRAF mutation and has already been treated with anti-PD-1 therapy. The trial…

This early-phase trial tested an oral drug called DCC-3084, alone or with other cancer treatments, in 29 people with advanced solid tumors that have MAPK pathway mutations (like certain lung, pancreatic, or skin cancers). The study aimed to find safe doses and see if tumors shrin…

This study tested a surgical method to prevent lymphedema (arm swelling) in people having lymph nodes removed for breast cancer or melanoma. The technique, called axillary reverse mapping with lympho-venous bypass, aims to preserve arm drainage while removing cancer-affected node…

This early-stage study tested a new drug called PF-07826390, given alone or with another drug (sasanlimab), in people with advanced solid tumors like lung, kidney, and colorectal cancers. The goal was to check safety and find the right dose. Only 10 people took part, and the stud…

This study tested a biosimilar (JPB898) against the original immunotherapy Opdivo, both combined with Yervoy, in 52 adults with advanced melanoma that could not be surgically removed. The goal was to see if the biosimilar works just as well. However, the trial was terminated earl…

This phase II trial tested a mix of a personalized dendritic cell vaccine and three immune-boosting drugs in people with advanced melanoma that no longer responded to PD-1/PD-L1 checkpoint inhibitors. The goal was to see if the combination could shrink tumors or slow their growth…

This study tested an experimental drug called vobramitamab duocarmazine in people with advanced prostate cancer and other solid tumors that stopped responding to standard treatments. The goal was to see if the drug could shrink tumors or slow cancer growth. The trial was terminat…

This early-phase trial tested a new drug (SAR444245) combined with an existing immunotherapy (cemiplimab) in 46 adults with advanced melanoma or squamous cell skin cancer that could not be surgically removed. The goal was to see if the combination shrank tumors. However, the stud…

This early-phase trial tested the safety and dosing of a new drug called modakafusp alfa, given alone or with pembrolizumab, in adults with advanced solid tumors or melanoma. The study aimed to find the highest safe dose and check for side effects. It was terminated early, so res…

This early-stage trial tested a modified virus (VSV-IFNbetaTYRP1) in 12 patients with advanced melanoma that had spread or could not be removed by surgery. The virus was designed to infect and kill melanoma cells while also boosting the immune system's attack. The main goals were…

This study tested whether combining two immunotherapy drugs (nivolumab and relatlimab) works better than nivolumab alone to keep melanoma from returning after surgical removal. It involved over 1,000 adults and teens with stage III or IV melanoma that had been completely removed.…

This study tested a new drug called CX-072 combined with other cancer treatments for adults with solid tumors or advanced melanoma. The goal was to see if the combination could shrink tumors. However, the study was stopped early and only 3 people took part, so we don't have enoug…

This early-phase study tested a new drug called KZR-261 in 61 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, find the right dose, and see if the drug could shrink tumors. The trial was terminated, but the…

This study tested a combination of two drugs—duvelisib (a pill) and nivolumab (an IV infusion)—in 13 people with advanced melanoma that had stopped responding to standard immunotherapy. The goal was to find a safe dose and see if the combination could shrink tumors or slow the di…

This study tested whether taking a pill containing gut bacteria (EDP1503) could help the immunotherapy drug pembrolizumab (Keytruda) work better in people with advanced melanoma. The trial included two groups: those who had never received anti-PD1 therapy and those whose cancer h…

This early-phase trial tested whether giving the immunotherapy drug STI-3031 directly into the lymph nodes or vessels (using a special device) is safe for people with in-transit melanoma, a type of skin cancer that spreads through lymph channels. Only 3 people took part before th…

This early-phase trial tested a new treatment called BT-001, a virus designed to infect and kill cancer cells, given alone or with the immunotherapy drug pembrolizumab. The study involved 31 people with advanced solid tumors like melanoma, lung cancer, or sarcoma that had spread.…

This study tested a new drug combination for people with metastatic melanoma (skin cancer that has spread). The goal was to find a safe dose of an experimental drug (APX005M) injected directly into tumors, combined with an approved immunotherapy (pembrolizumab) given through the …

This early-stage study tested a new drug called BDC-3042, alone or with another drug (cemiplimab), in 17 people with advanced cancers like breast, kidney, ovarian, head and neck, colorectal, lung, or melanoma. The main goal was to check safety and find the right dose. The study w…

This study tested a drug called niraparib in 22 adults with advanced solid tumors (like breast, lung, or pancreatic cancer) that have a specific genetic change called a PALB2 mutation. The goal was to see if the drug could shrink tumors or slow cancer growth. The study was stoppe…

This early-stage study tested a new drug called HFB301001 in 31 adults with advanced solid tumors (like sarcoma, kidney cancer, or melanoma) that had not responded to prior treatments. The main goal was to check the drug's safety and find the best dose. The study was terminated, …

This study tested a combination of three drugs (azacitidine, pembrolizumab, and epacadostat) in 70 people with advanced solid tumors, including lung and colorectal cancers. The goal was to see if the combination was safe and could shrink tumors. However, the trial was terminated …

This study tested whether adding an immune-boosting drug (NT-I7) to a standard immunotherapy (atezolizumab) could help people with advanced skin cancers like melanoma, Merkel cell carcinoma, and squamous cell carcinoma. The trial included 31 adults whose cancer had not responded …

This early-phase study tested a new drug called PF-07284890, alone or with another drug (binimetinib), in 65 people with advanced cancers that have a specific genetic change (BRAF V600 mutation), including cancers that spread to the brain. The trial was terminated early, but rese…

This early-stage study tested a new drug called ACTM-838 in 10 people with advanced solid tumors that no longer responded to standard treatments. The main goals were to check safety and find the right dose. The study was stopped early, so results are limited.

This phase 2 trial tested the drug tovorafenib (DAY101) in 23 people aged 12 and older with recurrent or progressive solid tumors that have specific genetic changes in the MAPK pathway. The goal was to see how many patients' tumors shrank or disappeared. The study was terminated …

This early study tested an experimental oral drug called IK-595 in people with advanced solid tumors that have specific RAS or RAF gene mutations. The goal was to check safety, dosing, and early signs of tumor shrinkage. The study was terminated before completion, so full results…

This phase 3 study tested whether adding an immunotherapy drug (spartalizumab) to two targeted therapy drugs (dabrafenib and trametinib) works better than the targeted drugs alone for people with advanced BRAF V600 mutant melanoma. The trial enrolled 568 participants but was term…

This early-stage trial tested a new drug, PF-07820435, alone or with another immunotherapy (sasanlimab) in 9 people with advanced solid tumors like lung, skin, or kidney cancer. The main goals were to check safety and find the right dose. The study was terminated early, so result…

This trial investigates whether a new, ultra-high-frequency ultrasound device can accurately measure the depth of skin melanomas before surgery. Currently, doctors must remove the tumor, measure its depth under a microscope, and then often perform a second surgery to remove more …

This early-phase trial tested a radioactive imaging agent called 68GaNOTA-Anti-MMR-VHH2 to see if it could safely highlight tumors on PET scans. It involved 13 adults with advanced solid tumors, breast cancer, or melanoma. The study was terminated early, so we have limited inform…

This study tested three portable imaging systems (MoleMapper, Visiomed, and confocal microscopy) to see how well they could detect melanoma compared to a dermatologist's exam. Seventeen people with suspicious moles participated. The goal was to find out if these devices could acc…

This study tested whether a device called the Sklip System, which uses artificial intelligence, could help people at home decide if a mole might be skin cancer. Only one person took part before the study was stopped early. The goal was to see if the AI could match or beat standar…

This phase 3 trial tested a vaccine called POL-103A (Seviprotimut-L) in 504 people with high-risk melanoma who had just had surgery. The goal was to see if the vaccine could prevent the cancer from coming back. However, the study was terminated early, so it is not known whether t…

This early-stage trial tested whether adding a device that creates electric fields (NovoTTF-200M) to standard radiation and immunotherapy is safe for people with melanoma that has spread to the brain. Only one person took part before the study was stopped early. The main goal was…

This study was designed to track side effects and quality of life in people aged 70 and older with advanced melanoma or non-small cell lung cancer who are starting immunotherapy. Researchers planned to monitor 40 participants for serious side effects and changes in daily well-bei…

This study is looking at whether tumor biopsies can help predict which patients with melanoma, non-small cell lung cancer, or head and neck cancer will respond to immunotherapy drugs called PD-1 or PD-L1 inhibitors. Researchers will collect tissue samples from about 152 adults be…

This study explores whether the community of bacteria living on the skin (the skin microbiome) plays a role in vitiligo—a condition that causes white patches—and in side effects from anti-PD-1 immunotherapy for advanced melanoma. Researchers will collect skin swabs from people wi…

This early-stage study tested whether inhaling the cancer drug afatinib works as well as taking it by mouth. Four healthy adult smokers received both forms in separate sessions to compare drug levels in the blood and lungs. The study was terminated early, so the findings are limi…

This study followed 28 adults with liver, colorectal, melanoma, or kidney cancers who received high-dose radiation therapy. Researchers collected blood samples before, during, and after treatment to track immune cells and other markers. The goal was to learn how the immune system…

This study tested a method called EPR oximetry to measure oxygen levels in skin tumors. Only 3 people took part before the study was stopped early. The goal was to see if this technique could track how tumors respond to oxygen therapy and standard cancer treatments.

This observational registry aims to learn about the health, wellbeing, and needs of people who were diagnosed with cancer between ages 18 and 39. Participants complete surveys every 6 to 12 months about anxiety, depression, social support, and financial distress. The registry als…